Does HHS enforcement discretion mean TB-500 is FDA approved?

No. Enforcement discretion is not FDA approval of a finished drug, not final 503A bulks-list placement by itself, and not an authorization for research-chemical retail as compounding.

What did LegitScript change on November 2, 2026?

LegitScript stated that offering one of the six covered peptides should not, by itself, prevent certification when the offering meets the HHS policy’s conditions and LegitScript’s other standards. That update is about certification review for healthcare businesses — not a change to peptide.prof’s research-use catalog rules.

Buyer notes

TB-500 after HHS enforcement discretion and LegitScript’s Nov 2026 update

Published November 2, 2026 · Updated November 2, 2026 · Research use only

TB-500 is one of six peptides named in HHS’s October 2026 interim 503A enforcement-discretion policy. On November 2, 2026, LegitScript said it opened certification review to covered offerings that meet that policy’s conditions. This note is for research buyers who need dated facts — not medical or compounding advice.

peptide.prof lists TB-500 as 5 mg and 10 mg lyophilized research vials with pack pricing on the product page. Stock follows the live inventory feed.

Open TB-500 research vials →

What HHS published (October 2026)

On 2026-10-28, HHS filed an interim enforcement-discretion policy concerning six peptide bulk drug substances for qualifying 503A compounders under stated conditions (Federal Register publication schedule noted in the public-inspection notice). TB-500 is in that appendix set alongside BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.

What this is not: FDA approval; final bulks-list rulemaking by itself; a 503B allowance; or a conversion of research catalogs into compounding pharmacies.

What LegitScript published (November 2, 2026)

LegitScript published guidance explaining the HHS policy for healthcare businesses and stated that its certification review approach was updated effective November 2, 2026 so that offering a covered peptide should not, by itself, block certification when policy conditions and LegitScript standards are met. LegitScript also stresses the peptides are not FDA-approved by virtue of enforcement discretion, and that advertising/payment platforms keep their own rules.

LegitScript: HHS peptide compounding policy — what healthcare businesses need to know

What it means for research buyers

Compounding under 503A and research-use retail are different channels. peptide.prof sells laboratory research materials only.
Do not read “enforcement discretion” or a certification-policy update as a human-use claim on a research vial page.
For live stock and pack prices, use the product page — this store does not invent SKUs or prices missing from inventory.

FAQ

Does HHS enforcement discretion mean TB-500 is FDA approved?: No. Enforcement discretion is not FDA approval of a finished drug, not final 503A bulks-list placement by itself, and not an authorization for research-chemical retail as compounding.
What did LegitScript change on November 2, 2026?: LegitScript stated that offering one of the six covered peptides should not, by itself, prevent certification when the offering meets the HHS policy’s conditions and LegitScript’s other standards. That update is about certification review for healthcare businesses — not a change to peptide.prof’s research-use catalog rules.
Can I buy TB-500 research vials on peptide.prof?: peptide.prof lists TB-500 as 5 mg and 10 mg lyophilized research vials with pack pricing on the product page. Stock follows the live inventory feed. Research use only. Not for human or veterinary use.

Research use only. Not for human or veterinary use. No dose or administration instructions on this site. peptide.prof does not compound under section 503A or 503B.